Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic <scp>AL</scp> amyloidosis

Rezk, Tamer; Davenport, Andrew; Gan, Jaslyn; Lachmann, Helen; Fontana, Marianna; Martinez‐Naharro, Ana; Sachchithanantham, Sajitha; Guillotte, Christianne; Mahmood, Shameem; Petrie, Aviva; Whelan, Carol; Pinney, Jennifer H.; Foard, Darren; Lane, Thirusha; Youngstein, Taryn; Wechalekar, Ashutosh; Hawkins, Philip N.; Gillmore, Julian D.

doi:10.1111/bjh.15675

Cited by 5 publications

(4 citation statements)

References 10 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bioimpedance Vector Analysis (BIVA) has recently been proposed to detect fluid overload and sarcopenia in AL amyloidosis [ 40 ]. It is a non-invasive method that allows the analysis of the body composition in a few seconds thanks to the detection of the impedance, or the “resistance” opposed by the body to the passage of an alternating electric current of very low intensity (400 µÅ) and high frequency (50 kHz).…”

Section: Malnutrition and Evaluation Of The Nutritional Statusmentioning

confidence: 99%

“…Rezk et al [ 40 ] recently demonstrated that bioelectrical impedance (BIA) allows for recognizing changes in body composition in AL amyloidosis. They found that nearly 95% of AL patients had significant fluid retention using BIA technology.…”

Section: Malnutrition and Evaluation Of The Nutritional Statusmentioning

confidence: 99%

“…In particular, they evaluated fluid overload by estimating the ratio of extracellular water (ECW)/to total body water (TBW) (ECW/TBW). They found that excess extracellular water at baseline predicted survival and was associated with failure to achieve a treatment response [ 40 ].…”

Section: Malnutrition and Evaluation Of The Nutritional Statusmentioning

confidence: 99%

See 2 more Smart Citations

Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis

Dongiglio

Monda

Palmiero

et al. 2023

JCM

View full text Add to dashboard Cite

Gastrointestinal involvement is a common clinical feature of patients with systemic amyloidosis. This condition is responsible for invalidating gastrointestinal symptoms, a significant macro and micronutrient deficit, and is a marker of disease severity. Gastrointestinal involvement should be actively sought in patients with systemic amyloidosis, while its diagnosis is challenging in patients with isolated gastrointestinal symptoms. The nutritional status in systemic amyloidosis plays an essential role in the clinical course and is considered a significant prognostic factor. However, the definition of nutritional status is still challenging due to the lack of internationally accepted thresholds for anthropometric and biochemical variables, especially in specific populations such as those with systemic amyloidosis. This review aims to elucidate the fundamental steps for nutritional assessment by using clinical and instrumental tools for better prognostic stratification and patient management regarding quality of life and outcomes.

show abstract

Section: Malnutrition and Evaluation Of The Nutritional Statusmentioning

confidence: 99%

Section: Malnutrition and Evaluation Of The Nutritional Statusmentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis

Dongiglio

Monda

Palmiero

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Hence, BIA might accurately estimate the body composition in terms of muscle and fat masses as well as water content in ATTRv patients; this might be an indirect measure of dysautonomia and gastrointestinal function. Although BIA has been used to evaluate sarcopenia in diabetic neuropathy and AL amyloidosis [24,25], to our knowledge, there have been no studies to have assessed body composition through bioimpedance analysis in ATTRv patients. Taken together, HGS and BIA might have a potential in the assessment of the severity of the disease and the beneficial effects of treatments.…”

Section: Introductionmentioning

confidence: 99%

Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength

et al. 2022

View full text Add to dashboard Cite

Background and aims. Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv) is caused by mutations in the TTR gene, leading to misfolded monomers that aggregate generating amyloid fibrils. The clinical phenotype is heterogeneous, characterized by a multisystemic disease affecting the sensorimotor, autonomic functions along with other organs. Patisiran is a small interfering RNA acting as a TTR silencer approved for the treatment of ATTRv. Punctual and detailed instrumental biomarkers are on demand for ATTRv to measure the severity of the disease and monitor progression and response to treatment. Methods. Fifteen patients affected by ATTRv amyloidosis (66.4 ± 7.8 years, six males) were evaluated before the start of therapy with patisiran and after 9-months of follow-up. The clinical and instrumental evaluation included body weight and height; Coutinho stage; Neuropathy Impairment Score (NIS); Karnofsky performance status (KPS); Norfolk QOL Questionnaire; Six-minute walking test (6 MWT); nerve conduction studies; handgrip strength (HGS); and bioimpedance analysis (BIA). Results. Body composition significantly changed following the 9-months pharmacological treatment. In particular, the patients exhibited an increase in fat free mass, body cell mass, and body weight with a decrease in fat mass. A significant increase after 9 months of treatment was observed for the 6 MWT. Coutinho stage, KPS, NIS, NIS-W, nerve conduction studies, Norfolk, COMPASS-31 scale, and HGS remained unchanged. Conclusions. BIA might represent a useful tool to assess the effects of multiorgan damage in ATTRv and to monitor disease progression and response to treatments. More evidence is still needed for HGS. Patisiran stabilizes polyneuropathy and preserves motor strength by increasing muscle mass after 9 months of treatment.

show abstract

Focused review on nutritional status of patients with immunoglobulin light chain amyloidosis

Grigoletti

Zuchinali

Lemieux-Blanchard

et al. 2022

Current Problems in Cancer

View full text Add to dashboard Cite

Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis

Cited by 5 publications

References 10 publications

Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis

Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis

Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength

Focused review on nutritional status of patients with immunoglobulin light chain amyloidosis

Contact Info

Product

Resources

About